About the Company
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.
Employees
13
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ABIO News
ABIO ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is ...
Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)?
15 Stocks Hedge Funds are Shorting. In this article, we are going to take a look at where ARCA Biopharma, Inc. (NASDAQ:ABIO) stands against the other stocks hedge funds are shorting. Short selling ...
ARCA biopharma Inc (HQ10.MU)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
ARCA biopharma amends subscription agreement with Oruka Therapeutics
WESTMINSTER, Colorado - ARCA biopharma, Inc., a company specializing in in vitro and in vivo diagnostic substances, announced on Monday an amendment to a previously agreed Subscription Agreement with ...
ABIO ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is ...
ARCA biopharma, Inc.
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on ...
ARCA biopharma, Inc. (ABIO)
15 Stocks Hedge Funds are Shorting. In this article, we are going to take a look at where ARCA Biopharma, Inc. (NASDAQ:ABIO) stands against the other stocks hedge funds are shorting. Short selling ...
ARCA biopharma Inc ABIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ARCA biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ARCA biopharma, Inc. (ABIO)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...